drugset / Trial / NCT04774874
A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers
Phase 2
Completed
209 enrolled
Follicum AB
CentroDerm GmbH · collabHair and Skin Institute, Charité, Berlin, Germany · collabproDERM GmbH · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This exploratory phase IIa, double blind, randomized, vehicle controlled, multicenter dose-finding trial will evaluate the safety, tolerability, and efficacy of FOL-005 topical formulation (at 0.1%, 0.5% and 1.5% strength) administered once daily (in the evening) for 16 weeks in healthy male subjects with androgenetic alopecia.
Timeline
- Start
- 2020-06-24
- Primary completion
- 2021-01-29
- Completion
- 2021-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FOL-005 | Unknown | 0.1 % | Topical |
| Subject | FOL-005 | Unknown | 0.5 % | Topical |
| Subject | FOL-005 | Unknown | 1.5 % | Topical |